CoChat
Sign Up
Cited by 396Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsCancer-related cognitive impairment studies

Marked gender differences in progression of mild cognitive impairment over 8 years

Open access
Lin, Katherine A., Choudhury, Kingshuk Roy, Rathakrishnan, Bharath G., Marks, David M., Petrella, Jeffrey R., Doraiswamy, P. Murali, Alzheimer's Disease Neuroimaging Initiative·2015·Alzheimer's & Dementia: Translational Research & Clinical Interventions
DOI 10.1016/j.trci.2015.07.001PMC PMC4593067
Open this paper in CoChat — free accountOpen PDF

Abstract

Introduction: This study examined whether, among subjects with mild cognitive impairment (MCI), women progressed at faster rates than men. Methods: We examine longitudinal rates of change from baseline in 398 MCI subjects (141 females and 257 males) in the Alzheimer's Disease Neuroimaging Initiative‐1, followed for up to 8 years (mean, 4.1 ± 2.5 years) using mixed‐effects models incorporating all follow‐ups (mean, 8 ± 4 visits). Results: Women progressed at faster rates than men on the Alzheimer's disease assessment scale‐cognitive subscale (ADAS‐Cog; P = .001) and clinical dementia rating‐sum of boxes (CDR‐SB; P = .003). Quadratic fit for change over time was significant for both ADAS‐Cog ( P = .001) and CDR‐SB ( P = .004), and the additional acceleration in women was 100% for ADAS‐Cog and 143% for CDR‐SB. The variability of change was greater in women. The gender effect was greater in apolipoprotein E ( APOE ) ε4 carriers. Discussion: Women with MCI have greater longitudinal rates of cognitive and functional progression than men. Studies to confirm and uncover potential mechanisms appear to be warranted. Trial Registration: ADNI ClinicalTrials.gov identifier: NCT00106899 .

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.trci.2015.07.001

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Women with mild cognitive impairment or AD have faster cognitive decline than men.

    “Our findings suggest that women are at risk for delayed identification of cognitive decline, yet more rapid trajectory of decline, suggesting increased risk of dementia and disability compared with men, consistent with research showing that women with mild cognitive impairment or AD have faster cognitive decline than men.32,33”

    From Sex differences in cognitive decline among US adults (2021) · cites this paper as [33]

    The Conclusions and Discussion report faster cognitive decline in women than men with mild cognitive impairment. The study does not establish the same comparison among people already diagnosed with Alzheimer's disease, so the “or AD” portion is unsupported by this source. (LLM, conf=0.87)

    Experimental — accuracy not yet measured

  • After diagnosis, women progress faster with more rapid cognitive and functional declines.

    “After diagnosis, women also progress faster with more rapid cognitive and functional declines [3–8]”

    From Sex-specific DNA methylation differences in Alzheimer’s disease pathology (2021) · cites this paper as [7]

    The Discussion and Conclusions report faster cognitive and functional decline in women than men with mild cognitive impairment (MCI). The claim says only “after diagnosis,” without specifying MCI; the paper does not establish the same finding for women diagnosed with Alzheimer’s disease or other conditions. (LLM, conf=0.82)

    Experimental — accuracy not yet measured

  • Our findings are consistent with studies showing that women with mild cognitive impairment or AD have faster decline in global cognition than men.

    “Our findings are consistent with studies showing that women with mild cognitive impairment or AD have faster decline in global cognition than men.32,33”

    From Sex differences in cognitive decline among US adults (2021) · cites this paper as [33]

  • Sex is an important factor that contributes to clinical and biological heterogeneity in Alzheimer's disease.

    “Sex is an important factor that contributes to the clinical and biological heterogeneities in Alzheimer’s disease (AD)”

    From Sex-specific DNA methylation differences in Alzheimer’s disease pathology (2021) · cites this paper as [7]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 34 · Cited by 396

Research works printed but not linked: 28

  1. [1]Mielke M.M. Vemuri P. Rocca W.A. Clinical epidemiology of Alzheimer's disease: Assessing sex and gender differences Clin Epidemiol 6 2014 37 48 24470773 PMC3891487
  2. [3]Seshadri S. Wolf P.A. Beiser A. Au R. McNulty K. White R. Lifetime risk of dementia and Alzheimer's disease. The impact of mortality on risk estimates in the Framingham Study Neurology 49 1997 1498 1504 9409336
  3. [5]Barnes L.L. Wilson R.S. Bienias J.L. Schneider J.A. Evans D.A. Bennett D.A. Sex differences in the clinical manifestations of Alzheimer disease pathology Arch Gen Psychiatry 62 2005 685 691 15939846
  4. [6]Holland D. Desikan R.S. Dale A.M. McEvoy L.K. Higher rates of decline for women and apolipoprotein E4 carriers AJNR Am J Neuroradiol 34 2013 2287 2293 23828104 PMC3894062
  5. [9]Plassman B.L. Langa K.M. McCammon R.J. Fisher G.G. Potter G.G. Burke J.R. Incidence of dementia and cognitive impairment, not dementia in the United States Ann Neurol 70 2011 418 426 21425187 PMC3139807
  6. [10]Irvine K. Laws K.R. Gale T.M. Kondel T.K. Greater cognitive deterioration in women than men with Alzheimer's disease: A meta analysis J Clin Exp Neuropsychol 34 2012 989 998 22913619
  7. [11]Altmann A. Tian L. Henderson V.W. Greicius M.D. Sex modifies the APOE-related risk of developing Alzheimer's disease Ann Neurol 75 2014 563 573 24623176 PMC4117990
  8. [12]Damolseaux J.S. Seeley W.W. Zhou J. Shirer W.R. Coppola G. Karydas A. Gender modulates the APOE4 effect in healthy older adults: Convergent evidence from functional brain connectivity and spinal fluid tau levels J Neurosci 32 2012 8254 8262 22699906 PMC3394933
  9. [13]Spremo-Potparevic B. Zivkovic L. Djelic N. Bajic V. Analysis of premature centromere division (PCD) of the X chromosome in Alzheimer patients through the cell cycle Exp Gerontol 39 2004 849 854 15130680
  10. [14]Bajic V. Spremo-Potparevic B. Zivkovic L. Siedlak S.L. Casadeus G. Smith M.A. The X-chromosome instability phenotype in Alzheimer's disease: A clinical sign of accelerating aging? Med Hypotheses 73 2009 917 920 19647374 PMC2787990
  11. [15]Ferrari R. Dawoodi S. Raju M. Thumma A. Hynan L.S. Maasumi S.H. Androgen receptor gene and gender specific Alzheimer's disease Neurobiol Aging 34 2013 2077.e19 2077.e20 PMC4012749 23545426
  12. [16]Scacchi R. Gambina G. Broggio E. Corbo R.M. Sex and ESR1 genotype may influence the response to treatment with donepezil and rivastigmine in patients with Alzheimer's disease Int J Geriatr Psychiatry 29 2014 610 615 24150894
  13. [17]Brown C. Choi E. Xu Q. Vitek M.P. Colton C.A. The ApoE4 genotype alters the response of microglia and macrophages to 17B-estradiol Neurobiol Aging 29 2008 1783 1794 17553597 PMC2597534
  14. [19]Henderson V.W. The epidemiology of estrogen replacement therapy and Alzheimer's disease Neurology 48 5 Suppl 7 2007 S27 S35 9153164
  15. [20]Jamshed N. Ozair F.F. Aggarwal P. Ekka M. Alzheimer disease in post-menopausal women: Intervene in the critical window period J Midlife Health 5 2014 38 40 24672205 PMC3955045
  16. [21]Janicki S.C. Park N. Cheng R. Lee J.H. Schupf N. Clark L.N. Estrogen receptor B variants modify risk for Alzheimer's disease in a multiethnic female cohort J Alzheimers Dis 40 2014 83 93 24326520
  17. [22]Lan Y.L. Zhao J. Li S. Update on the neuroprotective effect of estrogen receptor alpha against Alzheimer's disease J Alzheimers Dis 43 2015 1137 1148 25159676
  18. [23]Paganini-Hill A. Henderson V.W. Estrogen deficiency and risk of Alzheimer's disease in women Am J Epidemiol 140 1994 256 261 8030628
  19. [24]Skup M. Zhu H. Wang Y. Giovanello K.S. Lin J.A. Shen D. Sex differences in grey matter atrophy patterns among AD and aMCI patients: Results from ADNI Neuroimage 56 2011 890 906 21356315 PMC3085726
  20. [25]Gibbs R.B. Aggarwal P. Estrogen and basal forebrain cholinergic neurons: implications for brain aging and Alzheimer's disease-related cognitive decline Horm Behav 34 1998 98 111 9799621
  21. [27]Butler H.T. Warden D.R. Hogervorst E. Ragoussis J. Smith A.D. Lehmann D.J. Association of the aromatase gene with Alzheimer's disease in women Neurosci Lett 468 2010 202 206 19879925
  22. [28]Payami H. Zareparsi S. Montee K.R. Sexton G.J. Kaye J.A. Bird T.D. Gender difference in apolipoprotein E-associated risk for familial Alzheimer disease: a possible clue to the higher incidence of Alzheimer disease in women Am J Hum Genet 58 1996 803 811 8644745 PMC1914663
  23. [29]Bretsky P.M. Buckwalter J.G. Seeman T.E. Miller C.A. Poirer J. Schellenberg G.D. Evidence for an interaction between apolipoprotein E genotype, gender, and Alzheimer disease Alzheimer Dis Assoc Disord 13 1999 216 221 10609670
  24. [30]Fleisher A. Grundman M. Jack C.R. Jr. Peterson R.C. Taylor C. Kim H.T. Alzheimer’s Disease Cooperative Study Sex, apolipoprotein E epsilon 4 status, and hippocampal volume in mild cognitive impairment Arch Neurol 62 2005 953 957 15956166
  25. [31]Liu Y. Paajanen T. Westman E. Wahlund L.O. Simmons A. Tunnard C. AddNeuroMed Consortium Effect of APOE ε4 allele on cortical thicknesses and volumes: The AddNeuroMed study J Alzheimers Dis 21 2010 947 966 20693633
  26. [32]Ruitenberg A. Ott A. vanSweiten J. Hofman A. Breteler M. Incidence of dementia: Does gender make a difference? Neurobiol Aging 22 2001 575 580 11445258
  27. [35]Williams M.M. Storandt M. Roe C.M. Morris J.C. Progression of Alzheimer disease as measured by clinical dementia rating sum of boxes scores Alzheimers Dement 9 1 Suppl 2013 S39 S44 22858530 PMC3660405
  28. [36]Lin K.A. Doraiswamy P.M. When Mars versus Venus is not a cliché: Gender differences in the neurobiology of Alzheimer's disease Front Neurol 5 2015 288 25628598 PMC4290582

Authors
Lin, K. A., Choudhury, K. R., Rathakrishnan, B. G., Marks, D. M., Petrella, J. R., Doraiswamy, P. M., & Initiative, A. D. N.
Affiliations
  • Duke University (US)
  • Duke Medical Center (US)
Corresponding author
Doraiswamy, P. Murali
ORCID
Venue
Alzheimer's & Dementia: Translational Research & Clinical Interventions
Publisher
Wiley
Published
2015-07-21
Volume
1
Issue
2
Pages
103-110
ISSN
2352-8737 (ISSN-L)
DOI
10.1016/j.trci.2015.07.001
PMC
PMC4593067
OpenAlex
W2162941124
Cited by
396
References
34
Citations by year
2026: 33 · 2025: 52 · 2024: 40 · 2023: 46 · 2022: 40 · 2021: 46 · 2020: 40 · 2019: 38 · 2018: 30 · 2017: 14 · 2016: 17
FWCI
16.52
Type
journal article
Language
en
Open access
Licence
Locations
  • Alzheimer s & Dementia Translational Research & Clinical Interventions (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (U01 AG024904)
  • U.S. Department of Defense (W81XWH‐12‐2‐0012)
  • National Institute on Aging
  • National Institute of Biomedical Imaging and Bioengineering
  • BioClinica
  • Biogen Idec
  • Eisai
  • Eli Lilly and Company
  • Genentech
  • GE Healthcare
  • Innogenetics
  • Medpace
  • Merck
  • Meso Scale Diagnostics
  • Novartis
  • Pfizer
  • Servier
  • Synarc
  • Takeda Pharmaceutical Company
  • Canadian Institutes of Health Research
  • Alzheimer's Disease Neuroimaging Initiative
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cancer-related cognitive impairment studies
Keywords
mild cognitive impairment, gender differences, cognitive decline, disease progression, Alzheimer's disease, APOE ε4 carriers, ADAS-Cog, Clinical Dementia Rating, Alzheimer's Disease Neuroimaging Initiative

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review